

**Appl. No.** : 10/719,619  
**Filed** : November 20, 2003

### **AMENDMENTS TO THE CLAIMS**

1. (Original): An improved vaccine composition that includes an antigen, wherein the improvement comprises ribavirin.
2. (Original): The improved vaccine composition of Claim 1, wherein said antigen is a viral antigen.
3. (Original): The improved vaccine composition of Claim 1, wherein said antigen is obtained from a virus selected from the group consisting of hepatitis A virus, hepatitis B virus, and hepatitis C virus.
4. (Original): The improved vaccine composition of Claim 1, wherein said antigen is obtained from hepatitis C virus.
5. (Original): The improved vaccine composition of Claim 1, wherein the amount of ribavirin is at least 0.25mg.
6. (Original): The improved vaccine composition of Claim 1, wherein the amount of ribavirin is between about 0.25mg and 100mg.
7. (Original): The improved vaccine composition of Claim 1, wherein the amount of ribavirin is between about 0.25mg and 25mg.
8. (Original): The improved vaccine composition of Claim 1, wherein the amount of ribavirin is between about 0.25mg and 1mg.
9. (Original): The improved vaccine composition of Claim 1, wherein the amount of ribavirin is at least 0.1mg ribavirin per kg body weight of a subject receiving said composition.
10. (Original): The improved vaccine composition of Claim 1, wherein the amount of ribavirin is between about 0.1mg ribavirin to about 1.0 mg ribavirin per kg body weight of a subject receiving said composition.
11. (Original): The improved vaccine composition of Claim 1, wherein the amount of ribavirin is between about 1.1mg ribavirin to about 2.0 mg ribavirin per kg body weight of a subject receiving said composition.
12. (Original): The improved vaccine composition of Claim 1, wherein the amount of ribavirin is between about 2.1mg ribavirin to about 3.0mg ribavirin per kg body weight of a subject receiving said composition.

**Appl. No.** : 10/719,619  
**Filed** : November 20, 2003

13. (Original): The improved vaccine composition of Claim 1, wherein the amount of ribavirin is between about 3.1mg ribavirin to about 4.0mg ribavirin per kg body weight of a subject receiving said composition.

14. (Original): A method of making the improved vaccine composition of Claim 1 comprising:

providing an antigen;  
providing ribavirin; and  
combining said antigen and said ribavirin so as to make said improved vaccine composition.

15. (Original): The method of Claim 14, wherein said antigen is a viral antigen.

16. (Original): The method of Claim 14, wherein said antigen is obtained from a virus selected from the group consisting of hepatitis A virus, hepatitis B virus, and hepatitis C virus.

17. (Original): The method of Claim 14, wherein said antigen is obtained from hepatitis C virus.

18. (Original): The method of Claim 14, wherein the amount of ribavirin is at least 0.25mg.

19. (Original): The method of Claim 14, wherein the amount of ribavirin is between about 0.25mg and 100mg.

20. (Original): The method of Claim 14, wherein the amount of ribavirin is between about 0.25mg and 25mg.

21. (Original): The method of Claim 14, wherein the amount of ribavirin is between about 0.25mg and 1mg.

22. (Original): The method of Claim 14, wherein the amount of ribavirin is at least 0.1mg ribavirin per kg body weight of a subject receiving said composition.

23. (Original): The method of Claim 14, wherein the amount of ribavirin is between about 0.1mg ribavirin to about 1.0 mg ribavirin per kg body weight of a subject receiving said composition.

24. (Original): The method of Claim 14, wherein the amount of ribavirin is between about 1.1mg ribavirin to about 2.0 mg ribavirin per kg body weight of a subject receiving said composition.

25. (Original): The method of Claim 14, wherein the amount of ribavirin is between about 2.1mg ribavirin to about 3.0mg ribavirin per kg body weight of a subject receiving said composition.

26. (Original): The method of Claim 14, wherein the amount of ribavirin is between about 3.1mg ribavirin to about 4.0mg ribavirin per kg body weight of a subject receiving said composition.

27. (Original): A method of enhancing an immune response to an antigen comprising:

providing a subject the improved vaccine composition of Claim 1.

28. (Original): The method of Claim 25, wherein said antigen is a viral antigen.

29. (Original): The method of Claim 25, wherein said antigen is obtained from a virus selected from the group consisting of hepatitis A virus, hepatitis B virus, and hepatitis C virus.

30. (Original): The method of Claim 26, wherein said antigen is obtained from hepatitis C virus.

31. (Original): An improved method of enhancing an immune response to an antigen that includes providing a subject an antigen, wherein the improvement comprises providing ribavirin.

32. (Original): The improved method of Claim 31, wherein said antigen and said ribavirin are provided together.

33. (Original): The improved method of Claim 31, wherein said antigen and ribavirin are provided separately.

34. (New): A method of enhancing a production of antibodies specific for a viral antigen comprising:

identifying a subject in need of an enhanced production of antibodies specific for a viral antigen; and

providing to said subject an immunogenic composition comprising a viral antigen and ribavirin.

35. (New): The method of Claim 34, wherein the amount of ribavirin is at least 0.25mg.

**Appl. No.** : 10/719,619  
**Filed** : November 20, 2003

36. (New): The method of Claim 34, wherein the amount of ribavirin is between about 0.25mg and 100mg.

37. (New): The method of Claim 34, wherein the amount of ribavirin is between about 0.25mg and 25mg.

38. (New): The method of Claim 34, wherein the amount of ribavirin is between about 0.25mg and 1mg.

39. (New): The method of Claim 34, wherein the amount of ribavirin is at least 0.1mg ribavirin per kg body weight of a subject receiving said composition.

40. (New): The method of Claim 34, wherein the amount of ribavirin is between about 0.1mg ribavirin to about 1.0 mg ribavirin per kg body weight of a subject receiving said composition.

41. (New): The method of Claim 34, wherein the amount of ribavirin is between about 1.1mg ribavirin to about 2.0 mg ribavirin per kg body weight of a subject receiving said composition.

42. (New): The method of Claim 34, wherein the amount of ribavirin is between about 2.1mg ribavirin to about 3.0mg ribavirin per kg body weight of a subject receiving said composition.

43. (New): The method of Claim 34, wherein the amount of ribavirin is between about 3.1mg ribavirin to about 4.0mg ribavirin per kg body weight of a subject receiving said composition.

44. (New): The method of Claim 34, wherein said antigen is obtained from a virus selected from the group consisting of hepatitis A virus, hepatitis B virus, and hepatitis C virus.

45. (New): The method of Claim 34, wherein said antigen is obtained from hepatitis C virus.

46. (New): A method of enhancing a production of antibodies specific for a viral antigen comprising:

providing an immunogenic composition comprising a viral antigen and ribavirin to a subject; and

measuring the production of antibodies specific for said viral antigen.

47. (New): The method of Claim 46, wherein said measuring comprises measuring a reduction of viral load.

**Appl. No.** : 10/719,619  
**Filed** : November 20, 2003

48. (New): A method of treating or preventing a disease comprising:  
identifying a subject in need of treatment or prevention of a disease; and  
co-administering to said subject a composition comprising an antigen and a  
composition comprising ribavirin.
49. (New): The method of Claim 48, wherein the antigen and ribavirin are  
administered in a single composition.
50. (New): The method of Claim 48, wherein the disease is selected from the group  
consisting of the disease caused by hepatitis A virus, the disease caused by hepatitis B virus, and  
the disease caused by hepatitis C virus.